Treatments · Entity Annotation Prototype (beta)

2articles mentioning treatments

2treatment mentions

1distinct treatments extracted

0%of mentions human-reviewed

Active filtersEntity: Hepatic arterial infusion chemotherapy ×

Hepatic arterial infusion chemotherapy

This treatment is selected. Its supporting articles are shown below.

Hepatic arterial infusion chemotherapy2

Articles mentioning Hepatic arterial infusion chemotherapy

2 articles · page 1 of 1

Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial

bmjopen · abstract · 2026-02-23 · 1 matching annotations

77.4%

Hepatic arterial infusion chemotherapy Adebrelimab lenvatinib Intrahepatic cholangiocarcinoma oxaliplatin capecitabine gemcitabine NCT06208462 ICC

…e after curative surgery, with no standard neoadjuvant therapy. Hepatic arterial infusion chemotherapy (HAIC) has shown efficacy in locally advanced ICC, while immune…

Hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitors versus lenvatinib plus PD-1 inhibitors as first-line treatment for hepatocellular carcinoma with high tumour burden and portal vein tumour thrombus (CHANCE 2416): study protocol of a multicentre, retrospective, target trial emulation design

bmjopen · abstract · 2025-09-09 · 1 matching annotations

86.9%

Hepatic arterial infusion chemotherapy lenvatinib L+P First Hospital of China Medical University HCC Advanced-stage hepatocellular carcinoma

…ly systematic targeted and immunotherapy in current guidelines. Hepatic arterial infusion chemotherapy (HAIC) is reported as an effective intervention for rapid decre…

Browse treatments

Hepatic arterial infusion chemotherapy

Articles mentioning Hepatic arterial infusion chemotherapy

Neoadjuvant hepatic arterial infusion chemotherapy (HAIC) with GEMOX and lenvatinib in combination with adebrelimab for resectable high-risk recurrent intrahepatic cholangiocarcinoma (ICC): study protocol of the NEO-ERA-01 feasibility trial